Pharmaceutical TechnologyOriginal article
FDA widens Vertex’s Casgevy use for paediatric patients
RegulatoryapprovedCasgevyPositive
AI Analysis
Summary
FDA has expanded Vertex's Casgevy gene therapy to pediatric patients as young as two years old with sickle cell disease or thalassemia. This label widening extends the therapeutic reach of the therapy to younger patient populations.
Outcome Details
FDA expanded Casgevy eligibility to pediatric patients as young as two years old with sickle cell disease or thalassemia
Importance:7/10
Sentiment:
0.80
gene therapypediatriclabel expansionsickle cell diseasethalassemiaFDA approval
Related Companies
Read the original article
Published by Pharmaceutical Technology on July 2, 2026 10:18 AM